Literature DB >> 23399930

Metabolic syndrome in rheumatoid arthritis.

Manole Cojocaru1, Inimioara Mihaela Cojocaru, Isabela Silosi, Camelia Doina Vrabie.   

Abstract

Rheumatoid arthritis (RA) generally affects people between the ages of 20 and 50. Patients with RA have a significantly higher prevalence of the metabolic syndrome (MS) compared to the general population. The increased cardiovascular risk (CVR) associated with RA places this disease among the most widely studied. The duration of RA was associated with MS, implicating the role of inflammation in MS development. The presence of MS correlates with increased subclinical atherosclerosis. A positive correlation between prevalence of MS and worsening of functional status was found in patients with RA. Patients with rheumatoid arthritis have an increased risk and a higher mortality from cardiovascular diseases (CVD), the rheumatologist should be aware of those MS risk factors and attempt to modify them. This review summarizes recent advances in the field of MS in RA.

Entities:  

Keywords:  accelerated atherosclerosis; inflammation; metabolic syndrome; rheumatoid arthritis

Year:  2012        PMID: 23399930      PMCID: PMC3557423     

Source DB:  PubMed          Journal:  Maedica (Buchar)        ISSN: 1841-9038


  28 in total

Review 1.  Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?

Authors:  S Van Doornum; G McColl; I P Wicks
Journal:  Arthritis Rheum       Date:  2002-04

2.  Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis.

Authors:  M Boers; M T Nurmohamed; C J A Doelman; L R Lard; A C Verhoeven; A E Voskuyl; T W J Huizinga; R J van de Stadt; B A C Dijkmans; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

3.  Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis.

Authors:  Chi Chiu Mok; Gary Tin Choi Ko; Ling Yin Ho; Ka Lung Yu; Pak To Chan; Chi Hung To
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-02       Impact factor: 4.794

Review 4.  Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks.

Authors:  H B Townsend; K G Saag
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

5.  Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis.

Authors:  Marijn Vis; Michael T Nurmohamed; Gertjan Wolbink; Alexandre E Voskuyl; Margret de Koning; Rob van de Stadt; Jos W R Twisk; Ben A C Dijkmans; Willem F Lems
Journal:  J Rheumatol       Date:  2005-02       Impact factor: 4.666

6.  Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles.

Authors:  Wan-Hee Yoo
Journal:  J Rheumatol       Date:  2004-09       Impact factor: 4.666

Review 7.  Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions.

Authors:  L C Rall; R Roubenoff
Journal:  Rheumatology (Oxford)       Date:  2004-08-03       Impact factor: 7.580

8.  Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis.

Authors:  C Popa; M G Netea; T Radstake; J W M Van der Meer; A F H Stalenhoef; P L C M van Riel; P Barerra
Journal:  Ann Rheum Dis       Date:  2004-07-01       Impact factor: 19.103

9.  Glucocorticoids and insulin sensitivity in rheumatoid arthritis.

Authors:  Patrick H Dessein; Barry I Joffe; Anne E Stanwix; Berenice F Christian; Martin Veller
Journal:  J Rheumatol       Date:  2004-05       Impact factor: 4.666

Review 10.  Inflammation, the metabolic syndrome and cardiovascular risk.

Authors:  Russell P Tracy
Journal:  Int J Clin Pract Suppl       Date:  2003-03
View more
  8 in total

Review 1.  Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis.

Authors:  Jane Falconer; Anne N Murphy; Stephen P Young; Andrew R Clark; Stefano Tiziani; Monica Guma; Christopher D Buckley
Journal:  Arthritis Rheumatol       Date:  2018-06-04       Impact factor: 10.995

2.  Cutting Edge: Deletion of Ezrin in B Cells of Lyn-Deficient Mice Downregulates Lupus Pathology.

Authors:  Debasis Pore; Emily Huang; Dina Dejanovic; Neetha Parameswaran; Michael B Cheung; Neetu Gupta
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

3.  Prevalence of metabolic syndrome in patients with rheumatoid arthritis in Morocco: a cross-sectional study of 179 cases.

Authors:  Fatima Ezzahra Abourazzak; Samia Mansouri; Adil Najdi; Latifa Tahiri; Chakib Nejjari; Taoufik Harzy
Journal:  Clin Rheumatol       Date:  2014-03-20       Impact factor: 2.980

Review 4.  Metabolic syndrome: is equine disease comparable to what we know in humans?

Authors:  Antonia Ertelt; Ann-Kristin Barton; Robert R Schmitz; Heidrun Gehlen
Journal:  Endocr Connect       Date:  2014-06-03       Impact factor: 3.335

5.  Assessment of the usefulness of skin autofluorescence as an indicator of disease activity and of the risk of developing diabetes in patients suffering from rheumatoid arthritis.

Authors:  Sławomir Jeka; Katarzyna Kolossa; Paweł Żuchowski; Rafał Wojciechowski; Arnika Wilińska-Jankowska; Marzena Waszczak
Journal:  Reumatologia       Date:  2015-12-08

Review 6.  Transformation of fibroblast-like synoviocytes in rheumatoid arthritis; from a friend to foe.

Authors:  Mohammad Javad Mousavi; Jafar Karami; Saeed Aslani; Mohammad Naghi Tahmasebi; Arash Sharafat Vaziri; Ahmadreza Jamshidi; Elham Farhadi; Mahdi Mahmoudi
Journal:  Auto Immun Highlights       Date:  2021-02-05

7.  Single Cell RNA-Seq Analysis Identifies Differentially Expressed Genes of Treg Cell in Early Treatment-Naive Rheumatoid Arthritis By Arsenic Trioxide.

Authors:  Chunling Li; Tianshu Chu; Zhiyi Zhang; Yue Zhang
Journal:  Front Pharmacol       Date:  2021-05-24       Impact factor: 5.810

8.  Prevalence of Metabolic Syndrome in Treatment Naïve Rheumatoid Arthritis and Correlation With Disease Parameters.

Authors:  Purneshwar Kumar Pandey; Abhijit Swami; Tanuj Kumar Biswas; Riturag Thakuria
Journal:  Arch Rheumatol       Date:  2016-10-13       Impact factor: 1.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.